Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06922591 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A Phase 1 study of Lung Cancer and NSCLC, sponsored by Tango Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
- 12
- Study locations
NCT06922591: Recruiting Phase 1 study of Lung Cancer and NSCLC, sponsored by Tango Therapeutics.
NCT06922591 is a Phase 1 study of Lung Cancer and NSCLC that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 183 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06922591, a Phase 1 study of Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Tango Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
- 12
- Study locations
Study Summary
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Primary Outcome
To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805
Conditions Studied
Interventions
- DRUG mFOLFIRINOX
- DRUG RMC-6236
- DRUG TNG462
- DRUG RMC-9805
- DRUG gemcitabine/nab-paclitaxel
Study Locations (12)
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
- NEXT Dallas - Irving
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Colorado
- Sarah Cannon Research Institute Denver - Denver
Florida
- Mayo Clinic Jacksonville - Jacksonville
Indiana
- University of Indiana - Indianapolis
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2025-05-31 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT06922591 shows while recruiting
NCT06922591 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (80% lower).
The record links to 8 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which mFOLFIRINOX is the first listed.
NCT06922591 lists 12 locations in 10 states (New York, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT06922591 about?
NCT06922591 is a clinical study titled "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients". TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and ...
What is the current status of trial NCT06922591?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2025-05-31. Estimated completion is 2027-12.
What conditions does trial NCT06922591 study?
This clinical trial studies the following conditions: Lung Cancer, NSCLC, Thoracic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic.
What interventions are being tested in trial NCT06922591?
The interventions under investigation include: mFOLFIRINOX (DRUG), RMC-6236 (DRUG), TNG462 (DRUG), RMC-9805 (DRUG), gemcitabine/nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06922591?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06922591 being conducted?
This trial has 12 study locations across Arizona, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06922591's enrollment target sits among peer trials
183 136th of 409 higher than 274 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI